Wells upgrades Adient to Overweight on North American recovery

Wells Fargo upgraded Adient (ADNT) to Overweight from Equal Weight with a price target of $31, up from $24. The company should benefit from a North American recovery in limited volume production with “added help from its “strong transplant relationships,” namely Toyota, the analyst tells investors in a research note. Wells believes Adient’s North American production footprint is also an advantage. It sees a “positive valuation multiple inflection” given the company’s positive growth trajectory and margin expansion into 2026.